The European Medicines Agency is set to decide whether to back EU marketing approval for eight new drugs.
Eli Lilly/Almirall could this week learn whether the European Medicines Agency will recommend in favor of pan-EU marketing approval for lebrikizumab, their investigational treatment for moderate-to-severe atopic dermatitis and potential rival to Sanofi/Regeneron Pharmaceuticals’ blockbuster drug Dupixent (dupilimumab).
Lebrikizumab is among eight new products for which initial EU marketing authorization applications (MAAs) are listed as being up for an opinion on the
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.
The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.
